IFP Advisors
MLYS icon

IFP Advisors’s Mineralys Therapeutics MLYS Stock Holding History

IFP Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$25 Hold
1
– – ﹤0.01% 5121
2026
Q2 		$27 Hold
1
– – ﹤0.01% 5056
2026
Q1 		$27 Sell
1
-7
-88% -$205 ﹤0.01% 4900
2025
Q4 		$290 Buy
8
+6
+300% +$241 ﹤0.01% 4413
2025
Q3 		$76 Buy
+2
New +$43 ﹤0.01% 4587
2025
Q2 		– Hold
0
– – – 4349
2025
Q1 		– Hold
0
– – – 4103
2024
Q4 		– Hold
0
– – – 4420

Other funds holding MLYS

AP
Andera Partners Paris $176M AUM 1.8% 1-Year Est. Return
TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
FIA
FNY Investment Advisers New York $402M AUM 85.34% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

IFP Advisors's MLYS Position: Q3 2026 in Review

IFP Advisors held its Mineralys Therapeutics (MLYS) position steady in Q3 2026 at 1 share worth $25. The position accounts for ﹤0.01% of the portfolio, ranked #5121.

IFP Advisors first reported a position in MLYS in Q3 2025 and has held it in 5 quarters since. The position peaked at $290 in Q4 2025. 11 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.

  • IFP Advisors held 1 share of Mineralys Therapeutics worth $25 as of Q3 2026.
  • IFP Advisors left its Mineralys Therapeutics share count unchanged in Q3 2026.
  • Mineralys Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #5121 holding.
  • IFP Advisors first reported a position in Mineralys Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • IFP Advisors's Mineralys Therapeutics position peaked at $290 in Q4 2025.
  • 11 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.